Company ProfilePremium

Abcam plc

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Abcam plc - Healthcare showcase

Year Founded & Workforce

1998

1,750 Employees

Industry

Healthcare

Services

Western BlottingELISA KitsMultiplex AssaysELISPOT KitsGlobal Immunoassays In R&D Market
A

Abcam plc Employee Contacts

70 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Abcam plc Overview

Company Headquarters: Cambridge, UK

Founded: 1998

Workforce: ~1,750

Company Working: Abcam plc is a global life sciences company that discovers, develops, and distributes high-quality biological reagents and tools for research, drug discovery, and diagnostics. It works across the industry to help life scientists complete their projects more quickly. It collaborates with life science organizations to develop novel binders for drug discovery, in-vitro diagnostics, and therapeutics. It supplies over 110,000 products to two-thirds of the world's life scientists to research protein targets, including antibodies, proteins, lysates, biochemicals, kits, and assays. It has thirteen locations globally and operates in over 130 countries worldwide. It manufactures its products in specialized facilities and sources them from over four hundred partners worldwide.

Strategy

Abcam plc is focused on investing in emerging markets, across the world. It is also focusing on increasing its presence in the untapped markets in the Middle East. The company is also focused on sustaining its position in the antibody market. Abcam plc aims to achieve organic growth through partnerships and acquisitions. Also, the company plans to increase its core reagent business. It is also planning to increase its presence in South Korea, China, and Japan.

Company Snapshot

$291.1M

Revenue

1,750

Employees

1998

Founded

Cambridge, UK

Headquarters

SWOT Analysis

Strengths

  • Strong product portfolio with more than 100,000 products
  • Increasing geographical presence
  • Market leader in primary antibodies used in research
  • Strong market position
  • Wide distribution network
  • Diverse manufacturing facility

Weaknesses

  • Limited success outside core business
  • Lack of stability in performance
  • Issues related to management

Opportunities

  • Partnerships & acquisitions
  • Emerging markets
  • New product launches
  • Strategic acquisitions and mergers

Threats

  • Changing competitive landscape
  • Increasing market competition
  • Political and regulatory environment

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
January 2020AcquisitionAbcam Plc announced an acquisition of Expedeon’s Proteomics and Immunology business, which includes Innova and TGR Biosciences. This will help the company to provide Expedeon’s proteomics and immunology products and support so that the life science community to perform their research and development
February 2018Product LaunchAbcam Plc launched FirePlex-HT High-throughput Multiplex Immunoassays. It helps to deliver more data from a sample

Product Offering

  • Abcam plc
    • Western Blotting
    • ELISA Kits
    • Multiplex Assays
    • ELISPOT Kits
    • Global Immunoassays In R&D Market
    • HERG Screening

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 291.1 Mn in 2019 to USD 357.2 Mn in 2021.
Abcam plc — By Business Segment
Series (USD Mn)201920202021
Sales291.1330.8357.2
R&D Expenditure1.63.46.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.